U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07257484) titled 'Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors' on Nov. 20.
Brief Summary: This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal women with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool...